[Inhibition of nitric oxide synthesis during bacterial shock does not prevent development of resistant hypotension

Fiziolohichnyi Zhurnal (Kiev, Ukraine : 1994)
|August 20, 2005
PubMed

Insights

This study investigated nitric oxide's role in septic shock-induced hypotension in rats. Results indicate that resistant hypotension in severe sepsis is independent of nitric oxide signaling pathways.

Area of Science:

  • Microbiology
  • Pathophysiology
  • Pharmacology

Background:

  • Sepsis, a severe infection, can lead to septic shock with resistant hypotension.
  • The role of nitric oxide (NO) in the vascular dysfunction of septic shock remains incompletely understood.

Purpose of the Study:

  • To investigate the involvement of nitric oxide in the development of resistant hypotension during generalized purulent infection in a rat model.
  • To determine the efficacy of nitric oxide synthase (NOS) inhibition in mitigating hypotension and improving survival during septic shock.

Main Methods:

  • Wistar rats were infected with a mixture of Staphylococcus aureus and Pseudomonas aeruginosa.
  • Vascular preparations from rat aortas were used for in vitro studies.
  • Nitric oxide synthase inhibitors (L-NAME, S-methyl-thiourea) and methylene blue were administered during hypotension.

Main Results:

  • Infection induced a septic shock-like state with hypotension and reduced vascular tone.
  • Administration of NOS blockers or methylene blue resulted in only transient blood pressure increases and decreased survival rates.
  • In vitro experiments showed no acetylcholine-induced vasodilation in infected or treated vessels, despite preserved sensitivity to other agents.

Conclusions:

  • Resistant hypotension in the terminal stages of septic shock is nitric oxide-independent.
  • Interference with nitric oxide pathways does not improve outcomes and may worsen survival in this septic shock model.

Related Concept Videos

Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...